Targeting disease from multiple angles

 Innovation in medicines

Home / R&D / Innovation in medicines

Creating potentially life-changing medicines

Our journey is powered by pioneering science, continuous innovation and a deep commitment to understanding the complexities of human health.

We have a diverse and growing pipeline designed to target the underlying drivers of disease with precision.

Our approach to tackling disease

What we study - and why?

Within R&D, our scientists work to understand the underlying processes that cause disease, and the different approaches used to treat it, also known as therapeutic modalities. This enables us to discover new molecules and develop them into future medicines.

A new era of medicine

We've entered a new era of medicine, where scientific advances allow us to target disease drivers that were once considered ‘undruggable’. This includes identifying new biological signals, creating treatments that work inside cells and combining therapies to disrupt disease pathways more effectively.

By developing medicines that work in new ways, we aim to offer more options to people who have a limited choice of treatments today.

Why is understanding disease biology so important?

Researching disease biology helps us uncover the fundamental mechanisms of disease. By identifying the potential places to intervene with disease, we can develop more targeted and personalised treatments.

Our toolbox of therapeutic modalities

By having multiple potential ways to disrupt disease biology, we have the potential to prevent, slow and even cure diseases. A deep understanding of a wide range of therapeutic modalities is a key part of our scientific strength. Because diseases are complex, we have designed our portfolio so we can combine different modalities, with the aim of achieving a result greater than the sum of its parts.

What are therapeutic modalities?

Put simply, they’re different types of treatment used to intervene with disease processes. This could mean an antibody, a gene therapy or a vaccine – each designed to work in a distinct way to address underlying drivers of disease.

Therapeutic modalities enabling our innovative medicines

We use a broad range of therapeutic modalities to translate scientific insight into innovative medicines, applying different approaches to address complex diseases.

Biologics

Biologics

We are leveraging a diverse range of biomolecule modalities to target cells and proteins in the body with the potential for exceptional accuracy, potency, and affinity. Our biologics platforms aim to create first- or best-in-class antibody, peptide and protein therapeutics that address areas of high unmet medical need – including for the treatment of cancers and immune-related disorders.

Antibody drug conjugates

Combining the power of small molecule agents with the precision of antibodies, these targeted therapeutics have the potential to redefine chemotherapy regimens as we know them.

Radioconjugates

Radioconjugates are a novel drug modality that delivers radiation directly to cancer cells. Here we explain their mechanism of action and implications for targeted radiotherapy in cancer.

Multispecific antibodies

Multispecific antibodies are novel drug modalities that can bind simultaneously to two or more target proteins or bridge two different cells, to elicit a therapeutic effect to treat cancer and other diseases.

Bispecific antibodies

Unique in their ability to bind two targets at the same time, bispecific antibodies offer many possible combinations of therapeutics and have the potential to improve target specificity and outcomes.

T-cell engagers

As a novel type of multispecific antibody, T-cell engagers redirect the immune system’s T-cells to target diseased cells.
Therapeutic proteins

Peptide and protein therapeutics

Through our long-established expertise in protein engineering, we are advancing both conventional and novel classes of protein and peptide therapies against new and challenging disease targets.

Monoclonal and fragment antibodies

Well-known for their specificity and selectivity, we are harnessing our extensive antibody discovery and protein engineering platforms to create monoclonal and fragment antibodies for therapeutic applications.

Cell therapies

Cell therapies

We are developing innovative cell therapies across different disease areas. Advances in our understanding of the immune system are informing our cell therapy portfolio across a range of tumour types in oncology and across a wide range of immune-mediated diseases. Our goal in oncology is to develop cell therapies that empower and equip the immune system’s T cells to more effectively target cancer through next-generation T-cell therapies, including chimeric antigen receptor T-cell therapies (CAR-Ts) and T-cell receptor therapies (TCR-Ts). In immunology, we are developing cell therapies to target T-cell dysfunction, stabilising and resetting T-regulatory cells. In B-cell driven diseases, such as systemic lupus erythematosus (SLE), we are harnessing the body’s own immune system to help transform the treatment of refractory patients who have failed multiple therapies.

Cell therapies

As a promising and rapidly advancing field, cell therapy has the potential to transform medicine across disease areas where significant need exists.

Genomic medicines

Genomic medicines

Recent advances in genomics have helped transform drug discovery and clinical research towards precision medicine. This has created the opportunity to target the genetic drivers of rare and chronic disease to alter the course of disease and potentially enable long-lasting treatment. We are exploring a number of nucleotide-based modalities from oligonucleotides and RNA-based therapies as well as using CRISPR/Cas9 and adeno-associated viruses (AAVs) as therapeutic tools.

Gene therapy

We are exploring the potential of gene therapy to modify and even cure disease by editing the genes responsible for causing illness.

Oligonucleotide therapeutics

Oligonucleotide therapies have tremendous potential to enable long-lasting treatment with a precision medicine approach, by modulating cellular pathways in ways not previously possible.

In vivo expressed biologics (IVEBs)

Bringing together our knowledge of biologics discovery and development with gene editing, in vivo expressed biologics have the potential to stimulate tissues to produce biologics in a person’s own body and could transform how we treat infectious diseases.

Small molecules

Small molecules

We have a long history of discovering and developing orally delivered small molecule medicines by harnessing innovative approaches to drug design and delivery. By combining our range of knowledge, skills and experience across multiple disciplines, we are constantly advancing our capabilities to create new potential therapies for the future.

Small molecules

Small molecules have been a mainstay of pharmaceuticals for nearly a century, and we continue to innovate their discovery and development through approaches including machine learning, AI, and novel chemistry methods.

Collaborate with us

However innovative our science and however effective our medicines, we know that meaningful progress in healthcare is never achieved alone.

Learn more

Innovate with us

If you believe in the power of science to change lives, join us as we push the boundaries of research to deliver potentially life-changing medicines for patients.

Learn more

Veeva ID: Z4-80700
Date of preparation: August 2026